4CASHEN A,SHAH A, HELGET A,et al. A phase Ⅰ pharmacokinetie trial of decitabine administered as a 3-hour infusion to patientswith acute myelogenous leukemia(AML) or myelodysp lastic syndrome (MDS) [ J ]. Blood ( ASH Annual Meeting Abstracts), 2005,106 : Abstract 1854.
5LUBBERT M, DASKALAKIS M, KUNZMANN R ,et al. Nonelonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2'-deoxycytidine(decitabine) [ J ]. Leuk Res, 2004,28(12) :1267 - 1271.
6KANTARJIAN H, ISSA JP, ROSENFELD CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase Ⅲ randomized study [ J ]. Cancer, 2006, 106 ( 8 ) : 1794 - 1803.
7RUTER B, WIJERMANS PW, LUBBERT M. Results of 5-aza-2'- deoxycytidine retreatment in high-risk myelodysplasia patients [ J ]. Cancer,2006,106 ( 8 ) : 1744 - 1750.
8STONE MR. Are new agents really making a difference in MDS? [ J ]. Res Clin Haematol, 2008,21 (4) :639 - 646.
9Kun-Tsan LIN,Richard,Georges E Rivard.High-per-formance liquid chromatographic analysis of chemical stability of5-aza-2′-deoxycytidine[J].J Pharm Sci,1981,70(11):1228-1232.
